Mink to provide third quarter 2023 financial report and corporate update

New york, oct. 30, 2023 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its third quarter 2023 financial results via press release before the market opens on thursday, nov. 9, 2023.
INKT Ratings Summary
INKT Quant Ranking